Estrogen treatment for acromegaly

Pituitary

Volumn 15, Issue 4, 2012, Pages 601-607

  Shimon, Ilan ^a,b   Barkan, Ariel ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acromegaly; Estrogen; IGF 1; Selective estrogen receptor modulators; Somatostatin receptor ligands

Indexed keywords

CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; EVOREL 50; GESTODENE; GROWTH HORMONE; OCTREOTIDE; ORAL CONTRACEPTIVE AGENT; PEGVISOMANT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACNE; ACROMEGALY; ADULT; CASE REPORT; DRUG MECHANISM; ESTROGEN THERAPY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONAL CONTRACEPTION; HORMONE INHIBITION; HUMAN; HYPOPHYSIS ADENOMA; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION; REVIEW;

ACROMEGALY; ESTROGENS; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 84870362604     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0426-4     Document Type: Review

References (51)

1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Acromegaly consensus group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94: 1509-1517
2. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D (1998) Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139: 516-521
3. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93: 2957-2968
4. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ (2009) German pegvisomant observational study. The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3-S10
5. Albright F, Reifenstein EG Jr et al (1946) Effect of estrogens in acromegaly. Trans Conf Metab Asp Conval 12-13: 102-122
6. McCullagh EP, Beck JC, Schaffenburg CA (1955) Control of diabetes and other features of acromegaly following treatment with estrogens. Diabetes 4: 13-23
7. Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25: 693-721
8. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, HoKK(2003) Estrogen inhibitsGHsignaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 100: 1016-1021
9. Borski RJ, Tsai W, DeMott-Friberg R, Barkan AL (1996) Regulation of somatic growth and the somatotropic axis by gonadal steroids: primary effect on insulin-like growth factor I gene expression and secretion. Endocrinology 137: 3253-3259
10. Bermann M, Jaffe CA, Tsai W, DeMott-Friberg R, Barkan AL (1994) Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin. J Clin Invest 94: 138-145
11. Fisker S, Jorgensen JO, Vahl N, Orskov H, Christiansen JS (1999) Impact of gender and androgen status on IGF-I levels in normal and GH-deficient adults. Eur J Endocrinol 141: 601-608
12. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO (1987) Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64: 51-58
13. van den Berg G, Veldhuis JD, Frolich M, Roelfsema F (1996) An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 81: 2460-2467
14. Ovesen P, Vahl N, Fisker S, Veldhuis JD, Christiansen JS, Jorgensen JO (1998) Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab 83: 1662-1667
15. Dawson-Hughes B, Stern D, Goldman J, Reichlin S (1986) Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 6: 424-432
16. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA (1997) Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82: 550-555
17. Jørgensen JO, Christensen JJ, Krag M, Fisker S, Ovesen P, Christiansen JS (2004) Serum insulin-like growth factor I levels in growth hormone-deficient adults: influence of sex steroids. Horm Res 62(Suppl 1): 73-76
18. Jørgensen JO, Christensen JJ, Vestergaard E, Fisker S, Ovesen P, Christiansen JS (2005) Sex steroids and the growth hormone/insulin-like growth factor-I axis in adults. Horm Res 64(Suppl 2): 37-40
19. Cook DM, Ludlam WH, Cook MB (1999) Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 84: 3956-3960
20. Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen G (1988) The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 66: 1171-1180
21. Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin- like growth factor-I. J Clin Endocrinol Metab 95: 2486-2491
22. Cheng V, Faiman C, Kennedy L, Khoury F, Hatipoglu B, Weil R, Hamrahian A (2012) Pregnancy and acromegaly: a review. Pituitary 15: 59-63
23. Jaffe CA, Pan W, Brown MB, DeMott-Friberg R, Barkan AL (2001) Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. J Clin Endocrinol Metab 86: 4364-4370
24. Lau SL, McGrath S, Evain-Brion D, Smith R (2008) Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest 31: 255-261
25. Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155: 279-284
26. Weissberger AJ, Ho KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72: 374-381
27. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO (1996) Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study. J Clin Endocrinol Metab 81: 2250-2256
28. Kirklin OL, Wilder RM (1936) Follicular hormone administration in acromegaly. Proc Mayo Clin 11: 121
29. Mintz DH, Finster JL, Josimovich JB (1967) Effect of estrogen therapy on carbohydrate metabolism in acromegaly. J Clin Endocrinol Metab 27: 1321-1327
30. Hamwi GJ, Skillman TG, Tufts KC Jr (1960) Acromegaly. Am J Med 29: 690-699
31. Schwartz E, Echemendia E, Schiffer M, Panariello VA (1969) Mechanism of estrogenic action in acromegaly. J Clin Invest 48: 260-270
32. Deller JJ Jr, Di Raimondo VC, Grodsky GM, Forsham PH (1966) Acromegaly. The effects of various steroid hormones on the insulin-induced growth hormone response. Calif Med 104: 1-5
33. Josimovich JB, Mintz DH, Finster JL (1967) Estrogenic inhibition of growth hormone-induced tibial epiphyseal growth in hypophysectomized rats. Endocrinology 81: 1428-1430
34. Wiedemann E, Schwartz E (1972) Suppression of growth hormone- dependent human serum sulfation factor by estrogen. J Clin Endocrinol 34: 51-58
35. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ (1980) Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 69: 571-575
36. Parkinson C, Ryder WD, Trainer PJ (2001) Sensus acromegaly study group. The relationship between serum GH and serum IGFI in acromegaly is gender-specific. J Clin Endocrinol Metab 86: 5240-5244
37. Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93: 1324-1330
38. Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R (2003) Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 26: 347-352
39. Vallette S, Serri O (2010) Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13: 311-314
40. Cozzi R, Attanasio R, Oppizzi G, Orlandi P, Giustina A, Lodrini S, Da Re N, Dallabonzana D (1997) Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest 20: 445-451
41. Maiza JC, Castillo-Ros S, Matta M, Bennet A, Caron P (2011) Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. Pituitary. doi: 10.1007/S11102-010-0287-7
42. Attanasio R, Barausse M, Cozzi R (2003) Raloxifene lowers IGFI levels in acromegalic women. Eur J Endocrinol 148: 443-448
43. Dimaraki EV, Symons KV, Barkan AL (2004) Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 150: 481-487
44. Yakar S, Pennisi P, Wu Y, Zhao H, LeRoith D (2005) Clinical relevance of systemic and local IGF-I. Endocr Dev 9: 11-16
45. Hodish I, Barkan A (2008) Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4: 324-332
46. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: ameta-analysis. J Clin Endocrinol Metab 90: 4465-4473
47. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92: 4598-4601
48. Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A (1997) Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 177: 707-715
49. Rice VM (2002) Optimizing the dose of hormone replacement therapy. Int J Fertil Womens Med 47: 205-210
50. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333
51. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366: 2257-2266